RT Journal Article
SR Electronic
T1 Improving estimation of Parkinson’s disease risk - The enhanced PREDICT-PD algorithm
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.03.16.20037002
DO 10.1101/2020.03.16.20037002
A1 Jonathan P. Bestwick
A1 Stephen D. Auger
A1 Cristina Simonet
A1 Richard N. Rees
A1 Daniel Rack
A1 Mark Jitlal
A1 Gavin Giovannoni
A1 Andrew J. Lees
A1 Jack Cuzick
A1 Anette E. Schrag
A1 Alastair J. Noyce
YR 2020
UL http://medrxiv.org/content/early/2020/03/23/2020.03.16.20037002.abstract
AB Background We previously reported a basic algorithm to identify risk of Parkinson’s disease (PD) using published data on risk factors and prodromal features. Using this algorithm, the PREDICT-PD study identified individuals at increased risk of PD, using tapping speed, hyposmia and REM sleep behaviour disorder (RBD) as “intermediate” markers of prodromal PD until sufficient incident cases accrued.Objectives To develop and test an enhanced algorithm which incorporates these intermediate markers into the risk model.Methods Intermediate markers were incorporated into risk estimates, and likelihood ratios for both the presence and absence of risk factors were used. Risk estimates were compared using the enhanced and the basic algorithm in members of the PREDICT-PD pilot cohort.Results The enhanced PREDICT-PD algorithm yielded a much greater range of risk estimates than the basic algorithm (346 - 784-fold difference between the 10th and 90th centiles vs 10 12-fold respectively). There was a greater increase in risk of PD with increasing risk scores for the enhanced algorithm than for the basic algorithm (hazard ratios per one standard deviation increase in log risk of 2.73 [95% CI 1.68 – 4.45; p<0.001] versus 1.47 [95% CI 0.86 2.51; p=0.16] respectively). Estimates from the enhanced algorithm also correlated more closely with subclinical striatal DaT-SPECT dopamine depletion (R2=0.14, p=0.010 vs R2=0.043, p=0.17).Conclusions Incorporating the previous intermediate markers of prodromal PD and using likelihood ratios improved the accuracy of the PREDICT-PD prediction algorithm for PD.Competing Interest StatementAlastair Noyce--Dr. Noyce is funded by the Barts Charity. Dr. Noyce reports additional grants from Parkinson's UK, Virginia Kieley benefaction, UCL-Movement Disorders Centre, grants and non-financial support from GE Healthcare, and personal fees from LEK, Guidepoint, Profile, Roche, Biogen Bial and Britannia, outside the submitted work. Anette Schrag--Prof Schrag is employed by University College London and NHS National Institute for Health Research UCL Biomedical Research Centre. She has received grants from the European Commission, Parkinson's UK, GE Healthcare, Economic and Social Research Council (ESRC), International Parkinson's and Movement Disorders Society, University College London, National Institute of Health (NIHR), National Institute for Health Research ULCH Biomedical Research Centre; honoraria from Health Advances; advisory board fees from GE Healthcare, Roche, Biogen, Bial; and royalties from Oxford University Press for Rating Scales in PD, University College London Business. Andrew Lees is funded by the Reta Lila Weston Institute of Neurological Studies, University College London, Institute of Neurology and reports consultancies from: Britannia Pharmaceuticals and BIAL Portela. He also reports grants and/or research support from the Frances and Renee Hock Fund, and honoraria from Britannia, Profle Pharma, UCB, Roche, BIAL, STADA Nordic, Nordiclnfu Care, and NeuroDerm. Stephen Auger--Dr Auger is employed by Health Education England Jonathan Bestwick, Cristina Simonet, Richard Rees, Daniel Rack, Jack Cuzick, Gavin Giovannoni and Mark Jitlal report no relevant disclosures. Funding StatementThe PREDICT-PD study is funded by Parkinson's UK (G1606).Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesIt is the intention of the authors to make study data available for sharing